Search

Displaying results 811 - 820 of 10000 in total
  1. Drug

    Lidocaine

    go.drugbank.com/drugs/DB00281
    ApprovedInvestigationalVet approved

    Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication [T583]. … Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis.

    Mixtures: EZ-Relief, Lidothol ESSynonyms: 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
  2. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. … It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.

    Categories: Vasodilators Used in Cardiac DiseasesSynonyms: N-(2-Hydroxyethyl)nicotinamide nitrate, N-(2-Hydroxyethyl)nicotinamide nitrate (ester)
  3. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    in Pompe disease. … Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content.

  4. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]

  5. Target

    Major histocompatibility complex class I-related protein 1

    go.drugbank.com/bio_entities/BE0003573
    TargetHumans

    In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1.2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers

    Polypeptides: Major histocompatibility complex class I-related protein 1
  6. Target

    ATP synthase F(1) complex subunit gamma, mitochondrial

    go.drugbank.com/bio_entities/BE0003842
    TargetHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit gamma, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated

    Polypeptides: ATP synthase F(1) complex subunit gamma, mitochondrial
  7. Target

    ATP synthase F(0) complex subunit e, mitochondrial

    go.drugbank.com/bio_entities/BE0009021
    TargetHumans

    Part of the complex F(0) domain (PubMed:37244256) … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(0) complex subunit e, mitochondrialFunction: protein-containing complex binding
  8. Drug

    Secukinumab

    go.drugbank.com/drugs/DB09029
    ApprovedInvestigational

    [A249840] Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque

    Products: Fraizeron 150mg/ml solution for injection in pre-filled pen, Fraizeron 300mg/2ml solution for injection in pre-filled pen
  9. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).

    Mixtures: Suliqua Pen, Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in Diabetes
  10. Drug

    Zonisamide

    go.drugbank.com/drugs/DB00909
    ApprovedInvestigational

    The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] … Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.

    Categories: Compounds used in a research, industrial, or household setting